Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy
| Autor: | Deborah Wolbrette, Mario Gonzalez, Soraya Samii, et al |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: | |
| Zdroj: | Vascular Health and Risk Management, Vol 2010, Iss default, Pp 517-523 (2010) |
| Druh dokumentu: | article |
| ISSN: | 1176-6344 1178-2048 |
| Popis: | Deborah Wolbrette, Mario Gonzalez, Soraya Samii, Javier Banchs, Erica Penny-Peterson, Gerald NaccarelliPenn State Heart and Vascular Institute, Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, USAAbstract: Dronedarone, a new Class III antiarrhythmic agent, has now been approved by the US Food and Drug Administration for use in patients with atrial fibrillation or atrial flutter. Approval came in March 2009 due to the positive results of the ATHENA trial showing significant reductions in all-cause mortality and cardiovascular hospitalization with dronedarone use. A post hoc analysis of the ATHENA data also suggested a decrease in stroke risk with this agent. However, due to safety concerns in the heart failure population in the earlier ANDROMEDA trial, dronedarone is not recommended for patients with an ejection fraction 35% and no recent decompensated heart failure, dronedarone should be considered earlier than amiodarone in the treatment algorithm.Keywords: dronedarone, amiodarone, atrial fibrillation, atrial flutter |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|